Development of a bispecific Antibody Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia
A. D. Duckworth, C. Eberlein, V. Pollard, R. Bethell, J. R. Slupsky, O. Schon, J. F. Woolley, T. Thorn
This paper develops a bispecific antibody-drug conjugate targeting CD7 and CD33 for AML treatment, showing improved selectivity and safety in preclinical studies.
bioRxiv · Jul 17, 2022 · PreprintCancer Biology